Synonym
HTF 919; HTF919; HTF-919; SDZ HTF 919; SDZ-HTF 919; Tegaserod; Zelmac; Zelnorm
IUPAC/Chemical Name
Hydrazinecarboximidamide, 2-((5-methoxy-1H-indol-3-yl)methylene)-N-pentyl-
InChi Key
IKBKZGMPCYNSLU-RGVLZGJSSA-N
InChi Code
InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+
SMILES Code
CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
301.39
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Pan HC, Shen YQ, Loers G, Jakovcevski I, Schachner M. Tegaserod, a small compound mimetic of polysialic acid, promotes functional recovery after spinal cord injury in mice. Neuroscience. 2014 Sep 26;277:356-66. doi: 10.1016/j.neuroscience.2014.06.069. Epub 2014 Jul 9. PubMed PMID: 25014876.
2: Bushman J, Mishra B, Ezra M, Gul S, Schulze C, Chaudhury S, Ripoll D, Wallqvist A, Kohn J, Schachner M, Loers G. Tegaserod mimics the neurostimulatory glycan polysialic acid and promotes nervous system repair. Neuropharmacology. 2014 Apr;79:456-66. doi: 10.1016/j.neuropharm.2013.09.014. Epub 2013 Sep 22. PubMed PMID: 24067923; PubMed Central PMCID: PMC4618794.
3: Seeger JD, Quinn S, Earnest DL, Lembo A, Kuo B, Rivero E, Walker AM. The Zelnorm epidemiologic study (ZEST): a cohort study evaluating incidence of abdominal and pelvic surgery related to tegaserod treatment. BMC Gastroenterol. 2012 Nov 30;12:171. doi: 10.1186/1471-230X-12-171. PubMed PMID: 23198861; PubMed Central PMCID: PMC3536557.
4: Wood P. Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits? Naunyn Schmiedebergs Arch Pharmacol. 2012 Jan;385(1):1-3. doi: 10.1007/s00210-011-0694-y. Epub 2011 Oct 4. PubMed PMID: 21969099.
5: Higgins DL, Ero MP, Loeb M, Kersey K, Hopkins A, Beattie DT. The inability of tegaserod to affect platelet aggregation and coronary artery tone at supratherapeutic concentrations. Naunyn Schmiedebergs Arch Pharmacol. 2012 Jan;385(1):103-9. doi: 10.1007/s00210-011-0687-x. Epub 2011 Sep 8. PubMed PMID: 21901313.
